Expert Opin Biol Ther. 2011 Aug;11(8):991-5. doi: 10.1517/14712598.2011.577060. Epub 2011 Apr 11.
The irritable bowel syndrome (IBS) is a common disorder of unknown etiology. Recently, a group of dysregulated microRNAs (miRNAs) in blood microvesicles and in colon tissue have been identified in IBS patients. miRNAs have been shown to modulate specific biological processes such as differentiation, proliferation, apoptosis and metabolism. The ideal strategy would be to use specific miRNAs as both diagnostic and therapeutic tools to recover intestinal function and treat intractable gastrointestinal symptoms. In conclusion, further study of the functional role of miRNAs will lead to a better understanding of the dysregulation of intestinal pathways in IBS patients. The results may lead to preventive and/or therapeutic strategies that use small molecules (such as mimics or inhibitors of specific miRNAs) to affect genetic and epigenetic control. Future clinical trials may use microvesicle-associated miRNA-based therapies by using specific inhibitors/mimics of miRNA to target gene expression and treat IBS.
肠易激综合征（IBS）是一种病因不明的常见疾病。最近，在 IBS 患者的血液微泡和结肠组织中发现了一组失调的 microRNAs（miRNAs）。miRNAs 已被证明可以调节特定的生物学过程，如分化、增殖、凋亡和代谢。理想的策略是将特定的 miRNAs 用作诊断和治疗工具，以恢复肠道功能并治疗难治性胃肠道症状。总之，对 miRNAs 功能作用的进一步研究将导致对 IBS 患者肠道途径失调的更好理解。研究结果可能会导致使用小分子（如特定 miRNAs 的模拟物或抑制剂）来影响遗传和表观遗传控制的预防和/或治疗策略。未来的临床试验可能会使用基于微泡相关 miRNA 的治疗方法，通过使用特定的 miRNA 抑制剂/模拟物来靶向基因表达并治疗 IBS。
